PathWhiz

PathWhiz ID	Pathway	Meta Data
PW128662 View Pathway	drug action Lasmiditan Mechanism of Action Action Pathway Homo sapiens Lasmiditan is an oral 5HT1F agonist used for the acute treatment of migraine headache with or without aura. The utility of this medication is that it lacks vasoconstrictor effects such as those seen in triptans, and thus offers those with cardiovascular disease an alternative to triptans. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: September 08, 2023 at 15:05 Last Updated: September 08, 2023 at 15:05
PW176079 View Pathway	metabolic Lasmiditan Predicted Metabolism Pathway new Homo sapiens Metabolites of Lasmiditan are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: November 29, 2023 at 13:47 Last Updated: November 29, 2023 at 13:47
PW145673 View Pathway	drug action Lasofoxifene Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:21 Last Updated: October 07, 2023 at 16:21
PW176962 View Pathway	drug action Latamoxef Action Pathway Escherichia coli Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. Latamoxef exhibits an anti-bacterial mechanism of actyion. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 3 and an unknown action on 1A. Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Karxena Harford Created On: January 02, 2024 at 09:21 Last Updated: January 02, 2024 at 09:21
PW145561 View Pathway	drug action Latamoxef Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:05 Last Updated: October 07, 2023 at 16:05
PW176895 View Pathway	drug action Latanoprost Action Pathway Homo sapiens Latanoprost is a prostaglandin E1 analog that reduces the risk of NSAID-induced gastric ulcers. Latanoprost stimulates prostaglandin receptors on parietal cells in the stomach to reduce gastric acid secretion. Latanoprost activates prostaglandin EP3 receptors in parietal cells. Activation of this receptor triggers the Gi protein signaling cascade, inhibiting adenylate cyclase. Adenylate cyclase is responsible for converting ATP to cAMP, therefore, inhibition of adenylate cyclase reduces cytosolic cAMP concentration. cAMP is responsible for activating protein kinase A. With lower concentrations of cAMP, less protein kinase A is activated. Protein kinase A activates the proton pump in the luminal membrane of the parietal cell. The role of the proton pump is to secrete acid (H+) into the stomach lumen. With reduced protein kinase A activation, this decreases the activity of the proton pump, fewer H+ ions are pumped into the lumen, reducing the acidity and thus allowing stomach ulcers to heal and reducing the pain caused by the ulcers. Latanoprost may also promote ulcer healing by increasing mucus and bicarbonate secretion and thickening the mucosal bilayer so the mucosa can generate new cells. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: December 20, 2023 at 16:15 Last Updated: December 20, 2023 at 16:15
PW144767 View Pathway	drug action Latanoprost Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:23 Last Updated: October 07, 2023 at 14:23
PW176889 View Pathway	drug action Latanoprostene bunod Action Pathway Homo sapiens Latanoprostene bunod is a prostaglandin E1 analog that reduces the risk of NSAID-induced gastric ulcers. Latanoprostene bunod stimulates prostaglandin receptors on parietal cells in the stomach to reduce gastric acid secretion. Latanoprostene bunod activates prostaglandin EP3 receptors in parietal cells. Activation of this receptor triggers the Gi protein signaling cascade, inhibiting adenylate cyclase. Adenylate cyclase is responsible for converting ATP to cAMP, therefore, inhibition of adenylate cyclase reduces cytosolic cAMP concentration. cAMP is responsible for activating protein kinase A. With lower concentrations of cAMP, less protein kinase A is activated. Protein kinase A activates the proton pump in the luminal membrane of the parietal cell. The role of the proton pump is to secrete acid (H+) into the stomach lumen. With reduced protein kinase A activation, this decreases the activity of the proton pump, fewer H+ ions are pumped into the lumen, reducing the acidity and thus allowing stomach ulcers to heal and reducing the pain caused by the ulcers. Latanoprostene bunod may also promote ulcer healing by increasing mucus and bicarbonate secretion and thickening the mucosal bilayer so the mucosa can generate new cells. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: December 20, 2023 at 09:42 Last Updated: December 20, 2023 at 09:42
PW146422 View Pathway	drug action Latanoprostene bunod Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:09 Last Updated: October 07, 2023 at 18:09
PW063578 View Pathway	drug action Latrepirdine H1-Antihistamine Action Homo sapiens Latrepirdine is a tricyclic H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Carin Li Created On: September 24, 2017 at 12:39 Last Updated: September 24, 2017 at 12:39